Paratek Pharmaceuticals Inc (PRTK.OQ)
PRTK.OQ on NASDAQ Stock Exchange Global Market
9.01USD
15 Oct 2018
9.01USD
15 Oct 2018
Change (% chg)
$0.00 (+0.00%)
$0.00 (+0.00%)
Prev Close
$9.01
$9.01
Open
$9.37
$9.37
Day's High
$9.58
$9.58
Day's Low
$8.91
$8.91
Volume
183,200
183,200
Avg. Vol
136,973
136,973
52-wk High
$24.65
$24.65
52-wk Low
$8.69
$8.69
Consensus Recommendations
| Consensus Recommendation | Next Earnings (approx.) | Company Fiscal Year End Month |
Last Updated |
|---|---|---|---|
| Outperform | -0.69 | December | 16 Oct 2018 |
Analyst Recommendations and Revisions
| 1-5 Linear Scale | Current | 1 Month Ago |
2 Month Ago |
3 Month Ago |
|---|---|---|---|---|
| (1) BUY | 6 | 6 | 6 | 6 |
| (2) OUTPERFORM | 4 | 4 | 4 | 4 |
| (3) HOLD | 1 | 1 | 0 | 0 |
| (4) UNDERPERFORM | 0 | 0 | 0 | 0 |
| (5) SELL | 0 | 0 | 0 | 0 |
| No Opinion | 0 | 0 | 0 | 0 |
| Mean Rating | 1.55 | 1.55 | 1.40 | 1.40 |
Consensus Estimates Analysis
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| # of Estimates | Mean | High | Low | 1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Dec-18 | 10 | 10.92 | 69.50 | 0.00 | 1.85 |
| Quarter Ending Mar-19 | 3 | 2.53 | 6.60 | 0.00 | 8.40 |
| Year Ending Dec-18 | 11 | 14.82 | 69.80 | 0.05 | 17.06 |
| Year Ending Dec-19 | 11 | 39.21 | 185.30 | 10.60 | 52.72 |
| Earnings (per share) | |||||
| Quarter Ending Dec-18 | 9 | -0.69 | 1.11 | -1.07 | -0.81 |
| Quarter Ending Mar-19 | 2 | -0.98 | -0.88 | -1.08 | -0.60 |
| Year Ending Dec-18 | 10 | -3.39 | -1.69 | -3.86 | -3.17 |
| Year Ending Dec-19 | 10 | -3.08 | -0.07 | -4.27 | -2.22 |
| LT Growth Rate (%) | 1 | -40.40 | -40.40 | -40.40 | -- |
Historical Surprises
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Estimates vs Actual | Estimate | Actual | Difference | Surprise % |
|---|---|---|---|---|
| SALES (in millions) | ||||
| Quarter Ending Jun-18 | 0.04 | 0.04 | 0.00 | 6.67 |
| Quarter Ending Mar-18 | 0.00 | 0.01 | 0.01 | 488.24 |
| Quarter Ending Dec-17 | 3.12 | 5.07 | 1.95 | 62.30 |
| Quarter Ending Sep-17 | 0.55 | 0.01 | 0.54 | 97.82 |
| Quarter Ending Jun-17 | 2.89 | 7.51 | 4.63 | 160.23 |
| Earnings (per share) | ||||
| Quarter Ending Jun-18 | -0.93 | -0.94 | 0.01 | -1.48 |
| Quarter Ending Mar-18 | -0.90 | -0.91 | 0.01 | -0.55 |
| Quarter Ending Dec-17 | -0.75 | -0.78 | 0.03 | -4.35 |
| Quarter Ending Sep-17 | -0.94 | -0.77 | 0.17 | -18.09 |
| Quarter Ending Jun-17 | -0.95 | -0.66 | 0.29 | -30.89 |
Consensus Estimates Trend
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Current | 1 Week Ago |
1 Month Ago |
2 Month Ago |
1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Dec-18 | 10.92 | 10.92 | 10.91 | 12.12 | 1.85 |
| Quarter Ending Mar-19 | 2.53 | 2.53 | 2.97 | 2.97 | 8.40 |
| Year Ending Dec-18 | 14.82 | 14.82 | 13.73 | 15.09 | 17.06 |
| Year Ending Dec-19 | 39.21 | 39.21 | 42.25 | 42.79 | 52.72 |
| Earnings (per share) | |||||
| Quarter Ending Dec-18 | -0.69 | -0.69 | -0.70 | -0.68 | -0.81 |
| Quarter Ending Mar-19 | -0.98 | -0.98 | -0.98 | -0.98 | -0.60 |
| Year Ending Dec-18 | -3.39 | -3.39 | -3.43 | -3.41 | -3.17 |
| Year Ending Dec-19 | -3.08 | -3.08 | -2.95 | -3.04 | -2.22 |
Estimates Revisions Summary
| Last Week | Last 4 Weeks | |||
|---|---|---|---|---|
| Number Of Revisions: | Up | Down | Up | Down |
| Revenue | ||||
| Quarter Ending Dec-18 | 0 | 0 | 1 | 0 |
| Quarter Ending Mar-19 | 0 | 0 | 1 | 1 |
| Year Ending Dec-18 | 0 | 0 | 1 | 0 |
| Year Ending Dec-19 | 0 | 0 | 2 | 4 |
| Earnings | ||||
| Quarter Ending Dec-18 | 0 | 0 | 1 | 0 |
| Quarter Ending Mar-19 | 0 | 0 | 0 | 0 |
| Year Ending Dec-18 | 0 | 0 | 1 | 0 |
| Year Ending Dec-19 | 0 | 0 | 0 | 3 |
Earnings vs. 
Estimates- UPDATE 1-U.S. FDA panel backs approval of Paratek's antibiotic
- U.S. FDA panel backs approval of Paratek's antibiotic
- UPDATE 1-Paratek antibiotic not inferior to current treatments-FDA staff
- Paratek antibiotic not inferior to current treatments-FDA staff
- BRIEF-Paratek Pharmaceuticals Reports Q1 Loss Per Share $0.91